Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Innovent Biologics and Eli Lilly announced the presentation of six clinical studies on TYVYT® (sintilimab injection) at the ESMO Virtual Congress 2020 from September 19-21. The studies cover various cancers, including lung, gynecological, hepatocellular, and gastric cancers. Significant findings include the ORIENT-11 and ORIENT-12 studies demonstrating the efficacy of sintilimab in combination therapies for advanced lung cancer. These presentations aim to enhance understanding of the drug's efficacy and guide future treatments.
Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020. Joshua Smiley, the Chief Financial Officer, will engage in a virtual fireside chat at 8:40 a.m. Eastern Time. A live audio webcast will be available on Lilly's Investor website, with a replay accessible for 90 days post-event. Lilly, a leading healthcare company, is committed to discovering and creating medicines that improve lives worldwide.
Eli Lilly will participate in the Morgan Stanley Global Healthcare Conference on September 16, 2020. Joshua Smiley, CFO, will engage in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be accessible on Lilly's Investor website, alongside a replay available for 90 days.
Lilly, a global healthcare leader, focuses on developing life-changing medicines and enhancing disease understanding. For more details, visit www.lilly.com.
Eli Lilly's recent Phase 3 CENTURION study reveals that REYVOW™ (lasmiditan) significantly improves pain freedom in adults suffering from migraines. Results show participants taking REYVOW at 200 mg experienced 4.6 times greater odds of pain freedom at 2 hours compared to placebo, while those at 100 mg had 3.8 times greater odds. Additionally, REYVOW demonstrated differences in pain relief and sustained freedom from pain up to 48 hours. Safety findings align with earlier studies, confirming a tolerable profile.
Eli Lilly will conduct a webcast on September 21, 2020, at 3:00 PM EDT, to discuss its presentations at the 2020 ESMO Virtual Congress. Investors, media, and the public can access the live webcast via a link on Lilly's website. A replay will be available afterwards. Lilly is committed to discovering and delivering life-changing medicines to improve health outcomes globally.
Eli Lilly and Company (NYSE: LLY) has expanded its Lilly Insulin Value Program, introducing a $35 copay card to help individuals with diabetes manage their insulin costs. This program, effective from January 2021, is aimed at people with commercial insurance and the uninsured, alleviating financial burdens associated with insulin purchases. Lilly also noted the integration of this copay card into their broader affordability solutions, which support approximately 20,000 patients monthly. Lilly's initiatives include partnerships to raise awareness about insulin affordability and options available to patients.
Eli Lilly will present data from 20 oncology studies at the ESMO Virtual Congress from September 19-21, 2020. Notable findings include positive Phase 3 results for Verzenio in treating high-risk HR+, HER2- early breast cancer, marking it as the only CDK4 & 6 inhibitor with significant improvement in invasive disease-free survival. Additionally, Lilly will showcase data on Retevmo for RET fusion-positive cancers and CYRAMZA's efficacy in EGFR-mutated NSCLC. The emphasis is on advancing cancer treatment and enhancing patient outcomes through collaborative efforts.
Eli Lilly and Company (NYSE: LLY) announced leadership changes effective October 1, 2020. Patrik Jonsson has been appointed as senior vice president, president of Lilly USA, and Chief Customer Officer. He succeeds Ilya Yuffa, who is promoted to senior vice president and president of Lilly Bio-Medicines. Both leaders will report to CEO David A. Ricks. Jonsson's extensive experience in managing complex markets and Yuffa's leadership in U.S. Diabetes are expected to benefit the company as it prepares for new medicine launches.
The FDA has approved two new doses of Trulicity (dulaglutide) by Eli Lilly (NYSE: LLY), expanding its offerings to 3.0 mg and 4.5 mg. This decision follows positive results from the phase 3 AWARD-11 trial, which indicated significant reductions in A1C and body weight for patients with type 2 diabetes. The 4.5 mg dose achieved A1C reduction of -1.9% and weight loss of -10.4 pounds, while the 3.0 mg dose showed reductions of -1.7% in A1C and -8.8 pounds in weight. These new doses are expected in U.S. pharmacies by late September.
Full results from the EMPEROR-Reduced phase III trial revealed that Jardiance (empagliflozin) significantly reduced cardiovascular death or hospitalization due to heart failure by 25%. The trial, presented at ESC Congress 2020, included adults with heart failure and was compared to a placebo. Key findings showed a 30% reduction in heart failure hospitalizations and a slower decline in kidney function among those taking Jardiance. The FDA has granted Fast Track designation for Jardiance concerning heart failure and chronic kidney disease, emphasizing the urgency for new treatment options.